Born2conquer:

What's the charges like?

Trading 212 has a few transaction charges, including:

FX fee: 0.15% on currency conversions

Overnight interest: Charged on positions held in a CFD account after 17:00 ET

Stamp Duty Reserve Tax (SDRT): 0.5% on share purchases for stocks listed on the London Stock Exchange

PTM Levy: £1 per trade for orders over £10,000

FINRA Fee: $0.000166 x quantity sold

Transaction Fee (Securities and Exchange Commission): $0.0008% of the value of the sell order

Funding account fees: 0.7% fee applies to deposits made via card payments, Google Pay, Apple Pay, OnlineBankingPL, and Sofort after the first 2,000 GBP/EUR is deposited

Trading 212 also has the following free services:
Trading commission, Custody fee, Account creation, Membership fee, Statements, and Account closure.

Trading 212 converts funds at the live interbank rate, which is the same rate that banks use to convert currencies.

OakPearl:


Nice update.
Keep it up.

thanks

aremso:
Who remembered foxo which I put here around early this year, did almost 700% last week after been kept low for several months. Crazy market.!

I totally forgot about this guy , but am seeing 189% increase on it as I just checked. Missed the pull-out 😂

To the coin miners, how's business going?

3 Top Energy Stocks to Buy for Reliable dividend

Oil prices have remained volatile, with traders reacting to the latest production decision from OPEC+, the implications of a U.S. election win for President-elect Trump, and the prospect of weaker energy demand out of China. Crude futures (CLZ24) today have dropped below $70 per barrel, with Wall Street casting a wary eye toward Beijing.

When energy prices are relatively low, it can be an ideal time for investors to scoop up shares of dividend stocks to maximize yield. Despite commodity price volatility, many integrated oil majors in the energy sector remain attractive investment opportunities, offering healthy, steady income with high yield ratios.

In particular, ExxonMobil (XOM), Chevron (CVX), and Shell (SHEL) are all standout energy stocks for investors seeking passive income. These companies have historically provided substantial returns to shareholders through consistent dividend payouts, and their ability to generate healthy cash flows makes them particularly appealing to those looking for steady income in their investment portfolios.

#1. ExxonMobil Stock
Headquartered in Texas, ExxonMobil (XOM) is a global leader in the oil, gas, and carbon capture industries, best known for its extensive operations in the exploration, production, and refining of oil and natural gas (NGZ24). In the most recent quarter, ExxonMobil produced an average of 4.6 million barrels of oil equivalent daily, and commands the largest market capitalization of $532 billion in the oil industry.

ExxonMobil's shares have climbed by 21.4% year-to-date, almost keeping pace with the broader S&P 500 Index's ($SPX) gains.
The company has a remarkable history of dividend payments, consistently increasing its payments for the past 42 years to establish its status as a Dividend Aristocrat. The oil giant is currently paying quarterly dividend of $0.99 per share, which translates to a yield of 3.27% at current levels - significantly higher than the S&P average of 1.5%.

During the Q3 earnings call, CEO Darren Woods stated, "We understand how important the dividend is to our investors, particularly our millions of retail shareholders. We remain committed to a sustainable, competitive, and growing dividend, which is a key component of the attractive total shareholder return we are delivering."

Despite fluctuations in oil prices, ExxonMobil paid out $12.3 billion in dividends so far in 2024, demonstrating its strong balance sheet and healthy cash flow. In Q3 2024, the company generated $17.6 billion in operating cash flow and $11.3 billion in free cash flow. The balance sheet remained robust, with a $27 billion cash balance and a net debt-to-capital ratio of 5%.

Analysts have a “moderate buy” rating on XOM stock, with a mean price target of $130.82. This reflects more than 8% upside potential from the current price.



#2. Chevron Stock
Based in California, Chevron (CVX) is one of the world's leading integrated energy companies, actively engaged in all sectors of the oil, natural gas, and geothermal energy industries. With a market valuation of $280.5 billion, Chevron is the only energy company listed on the 30-stock Dow Jones Industrial Average ($DOWI).

CVX stock has underperformed the broader market this year, up about 5% for 2024 amid weakness in oil prices.


Chevron is a compelling option for dividend-seeking investors, having consistently increased its annual dividend for the last 36 years. It currently offers a high yield of 4.15%, with a quarterly payout of $1.63 per share. The payout ratio stands at an impressive 55.9%.

On Nov. 1, CVX shares surged by 2.8% following the announcement of solid third-quarter results that exceeded analysts' expectations across both lines. Revenue reached $50.6 billion, while adjusted earnings per share of $2.51 surpassed the estimate of $2.47.

During Q3, the oil giant increased its global production by 7%, now producing 3.4 million barrels daily, surpassing ExxonMobil. The acquisitions of PDC Energy and assets in the Permian Basin have notably boosted production volumes.

Over the last two decades, Chevron has transformed into a cash-generating powerhouse. In Q3, it reported operating cash flow of $9.7 billion, supporting share buybacks and dividend payments.

Looking ahead, Chevron is heavily investing in its resource portfolio, initiating key projects in the Gulf of Mexico, Kazakhstan, and Tahiti fields, which are projected to increase supply production by 300,000 BOE/d by 2025.

To strengthen its balance sheet, Chevron is divesting lower-margin assets. Last month, the company announced the sale of its Canadian assets to Canadian Natural Resources for $6.5 billion. It also plans to sell its less profitable assets in Congo and Alaska in the upcoming quarter. These sales are expected to significantly enhance its financial position.

Analysts rate CVX stock a “moderate buy” with a mean price target of $169.38, indicating an expected upside potential of approximately 8.5%.


#3. Shell Stock
Based in London, Shell Plc (SHEL) is one of the oldest players in the oil industry, boasting a rich history that spans over a century. The company operates primarily across energy and petrochemical segments, exploring for, producing, and refining petroleum products. Currently, it holds a substantial market capitalization of $208 billion.

U.S.-traded shares of Shell stock have added just about 1% year to date, reflecting energy price weakness.


Shell offers a quarterly dividend payout of $0.69 per share, yielding 4.10% at current levels. The energy giant also recently announced a stock buyback program of $3.5 billion over the next three quarters.

On Oct. 31, Shell reported an adjusted Q3 profit of $6.03 billion, or $1.92 per share - down 4% year over year, but better than Wall Street expected, as higher liquefied natural gas (LNG) prices offset weakness in the chemical segment. However, revenue of $72.5 billion fell short of consensus expectations.

During Q3, Shell generated a healthy $14.68 billion in cash flow from operations, which surpassed estimates, and reported $10.8 billion in free cash flow. Its net debt-to-capitalization ratio improved to approximately 15.7%, down from 17.3% a year ago.

Overall, analysts remain bullish on SHEL stock, with a consensus "moderate buy" rating from the 19 in coverage. The average 12-month price target is $80, implying an upside potential of more than 21% from current levels.


© 2024 Barchart.com, Inc. All Rights Reserved.

TARGET TECHNICAL ANALYSIS EARLY MARKET COMMENTS 13 NOVEMBER 2024

Not a time to fear. Inflation report is likely to favour the market, lower than forecast or worst equal to forecast. So bulls are still fulling.

Sometimes I wonder why majority of guys don't discover the fastest way to multiply naira in Nigeria which is trading US stocks, am sure just a matter of time this space will create millionaire in dollars then billionaire in naira. No stock can do 100% on nse in a week

Tpst did 2800% last year October in 3days
Foxo had done 600% in a day last week
GNS did over 100% yesterday
Drug has done ove 700% few weeks ago
Ensc has done over 300% in one week

OakPearl:


Best U.K. broker any day should be Trading 212.

If you're in Nigeria, you may want to avoid that platform.

Penboy:


If you're in Nigeria, you may want to avoid that platform.

Why? I have been using them for years now.

TARGET TECHNICAL ANALYSIS EARLY MARKET COMMENTS 14 NOVEMBER 2024
Market overbought, risk looks high,now a second Asian Country has brought out stimulus package too like China.

Market may pullback,but blockchain looks strong with energy sector equally attempting to start rising.

We should monitor our stop loss, take some profits and then wait for pullbacks to buy(but most buys will be high risk at this point)

bastardson:


Why? I have been using them for years now.

Recently, they've been after my neck for verification purposes o.

I Don submit document tire o. Hopefully they accept all.

Calm down bro.... It's also one of the fastest way to be financially ruined. It could swing both ways.




[quote author=aremso post=132858510]Sometimes I wonder why majority of guys don't discover the fastest way to multiply naira in Nigeria which is trading US stocks, am sure just a matter of time this space will create millionaire in dollars then billionaire in naira. No stock can do 100% on nse in a week

Tpst did 2800% last year October in 3days
Foxo had done 600% in a day last week
GNS did over 100% yesterday
Drug has done ove 700% few weeks ago
Ensc has done over 300% in one week

2 Stocks That Could Create Lasting Generational Wealth


Patience should pay off if investors hold these businesses over many years.
Both companies have been paying dividends for decades.
Motley Fool Issues Rare “All In” Buy Alert
Time is on your side with these successful stocks.

If you're looking to create enduring wealth, the stock market is a great place to focus your attention. Businesses can grow their earnings power for decades, and some of the best companies have been rewarding shareholders with positive returns for over a century. Consider a company like Procter & Gamble, which has been paying out a dividend since the 90s -- the 1890s, that is.

Yet it's a challenge to identify stocks that can maintain their strong market positions for many decades, and there's always the risk of a major industry or technology shift impairing a previously successful business. That's why it pays to construct a portfolio of several world-class businesses. That way you aren't too dependent on any single company.

With that in mind, let's look at a few stocks that, from today's vantage point, seem poised to produce wealth over the long term.

1. Walmart
Walmart (WMT -0.04%) has been creating millionaires (beyond just the Walton family) for many generations. But there's plenty of room for this retailing giant to extend that momentum. Just take a look at the latest financial results that show how the company is winning with its core shoppers while extending into new markets and demographics.

NYSE: WMT
Walmart
Today's Change
(-0.04%) -US$0.04
Current Price
US$84.43
Customer traffic was up 4% year over year this past quarter even as average spending rose 1%. The e-commerce segment jumped 22%. That division is already worth over $100 billion in annual sales and is bringing more high-income shoppers into the Walmart brand. You can bet management will lean heavily on growth there to keep pushing earnings higher in the coming years. Walmart is also investing aggressively in digital advertising, which has been a big source of income for rival Amazon.

Those growth initiatives help explain why Walmart pays a modest dividend yield of below 1% as of mid-November. Yet investors who hold this stock for decades should benefit from the company's aggressive spending in those attractive categories.

2. McCormick
McCormick (MKC -2.63%) hasn't had the best post-pandemic period, yet that's no reason to avoid the stock for this consumer foods producer. It dominates several attractive categories in the spice, flavorings, and sauces niches with global brands like Cholula, Old Bay, and French's. That premium market position has helped it protect profit margins despite having to pass along higher prices to consumers over the past two years and dampening demand in the process.


Those price hikes have slowed to a crawl along with McCormick's decelerating costs in recent quarters. In Q3, the company returned to global volume growth as average selling prices declined slightly. "We expect this momentum to continue into the fourth quarter," CEO Brendan Foley said in an early October press release.

Sure, the 3% sales uptick that most Wall Street analysts expect in 2025 doesn't sound exciting. You could find faster organic growth from rivals like PepsiCo, which also happens to pay a higher dividend yield today.



NYSE: MKC
McCormick
Today's Change
(-2.63%) -US$1.97
Current Price
US$72.95
McCormick's more focused portfolio, though, should pave the way for many more years of market share growth and improving profitability. That's a recipe for market-beating returns from here for a stock that's trailed the market through the 2024 rally.

If you're concerned about the timing of McCormick's rebound, you might want to watch the next few quarterly reports for concrete signs that the business is again ready to grow both sales volumes and average prices. Yet patient investors focused on the long term should consider adding the food specialist to their portfolios while there's still some uncertainty keeping its valuation relatively low.




© 1995 - 2024 The Motley Fool. All rights reserved.

CARS.COM LIKELY TO PERFORM WELL IN TECH SECTOR
My writing style may be a bit different from what folks here are used to; and I do not intend to derail it either, but rather share technical analysis ideas...

In the Software industry under Technology sector, there this stock I've been monitoring for the past few weeks - CARS.COM. Technically, the stock is building momentum. Intend to start accumulating from 18 and wait until 16 circa (if it can pullback to this level).

PLAN YOUR TRADES AND TRADE YOUR PLANS

DESPITE Q3 LOSS, AST SPACEMOBILE REMAINS A BUY
The level between 19.30 - 23 looks strong for ASTS, holding price since late September; and with Q3 loss declared by the company, the price still got rejected at this level. There is high possibility that buyers are accumulating at this mentioned level. Will ASTS witness upward movt in coming weeks. A price close below 17 is not favourable!

PLAN YOUR TRADES AND TRADE YOUR PLANS

Celestialsword:

2 Stocks That Could Create Lasting Generational Wealth


Patience should pay off if investors hold these businesses over many years.
Both companies have been paying dividends for decades.
Motley Fool Issues Rare “All In” Buy Alert
Time is on your side with these successful stocks.

If you're looking to create enduring wealth, the stock market is a great place to focus your attention. Businesses can grow their earnings power for decades, and some of the best companies have been rewarding shareholders with positive returns for over a century. Consider a company like Procter & Gamble, which has been paying out a dividend since the 90s -- the 1890s, that is.

Yet it's a challenge to identify stocks that can maintain their strong market positions for many decades, and there's always the risk of a major industry or technology shift impairing a previously successful business. That's why it pays to construct a portfolio of several world-class businesses. That way you aren't too dependent on any single company.

With that in mind, let's look at a few stocks that, from today's vantage point, seem poised to produce wealth over the long term.

1. Walmart
Walmart (WMT -0.04%) has been creating millionaires (beyond just the Walton family) for many generations. But there's plenty of room for this retailing giant to extend that momentum. Just take a look at the latest financial results that show how the company is winning with its core shoppers while extending into new markets and demographics.

NYSE: WMT
Walmart
Today's Change
(-0.04%) -US$0.04
Current Price
US$84.43
Customer traffic was up 4% year over year this past quarter even as average spending rose 1%. The e-commerce segment jumped 22%. That division is already worth over $100 billion in annual sales and is bringing more high-income shoppers into the Walmart brand. You can bet management will lean heavily on growth there to keep pushing earnings higher in the coming years. Walmart is also investing aggressively in digital advertising, which has been a big source of income for rival Amazon.

Those growth initiatives help explain why Walmart pays a modest dividend yield of below 1% as of mid-November. Yet investors who hold this stock for decades should benefit from the company's aggressive spending in those attractive categories.

2. McCormick
McCormick (MKC -2.63%) hasn't had the best post-pandemic period, yet that's no reason to avoid the stock for this consumer foods producer. It dominates several attractive categories in the spice, flavorings, and sauces niches with global brands like Cholula, Old Bay, and French's. That premium market position has helped it protect profit margins despite having to pass along higher prices to consumers over the past two years and dampening demand in the process.


Those price hikes have slowed to a crawl along with McCormick's decelerating costs in recent quarters. In Q3, the company returned to global volume growth as average selling prices declined slightly. "We expect this momentum to continue into the fourth quarter," CEO Brendan Foley said in an early October press release.

Sure, the 3% sales uptick that most Wall Street analysts expect in 2025 doesn't sound exciting. You could find faster organic growth from rivals like PepsiCo, which also happens to pay a higher dividend yield today.



NYSE: MKC
McCormick
Today's Change
(-2.63%) -US$1.97
Current Price
US$72.95
McCormick's more focused portfolio, though, should pave the way for many more years of market share growth and improving profitability. That's a recipe for market-beating returns from here for a stock that's trailed the market through the 2024 rally.

If you're concerned about the timing of McCormick's rebound, you might want to watch the next few quarterly reports for concrete signs that the business is again ready to grow both sales volumes and average prices. Yet patient investors focused on the long term should consider adding the food specialist to their portfolios while there's still some uncertainty keeping its valuation relatively low.




© 1995 - 2024 The Motley Fool. All rights reserved.

You subscribe to Motley fool?

Penboy:


You subscribe to Motley fool?

yes

BuchyD:
Calm down bro.... It's also one of the fastest way to be financially ruined. It could swing both ways.

Bro. Sure if u one doesn't know what he or she is doing, I select my battle to fight and I follow my strategies. Still remains the best for me. Have watched several YouTube videos of those who started with small money of 2-5k and they have grown the money to millions today still in the same market that looks tough some how so those guys don't have 2 heads. I play mostly in health sector cos that Is where I know there are catalyst that can give 100-300% in a day are. TSTP if I don't get the ticker wrong did 2,800% in 3 days. Oct last year. So I believe Fortune will be made here though not for Fainthearted and lazy but VERY ACHIEVABLE.

Celestialsword:
yes

Okay.
Well done.

S&P500 INDEX IN A PULLBACK, BULLISH TREND STILL INTACT
With the pullback of S&P500 index, this is the time to cherry pick "strong" stocks to buy. The trend of the index is bullish and even the short term daily bullish outlook is still intact. Expecting a re-bounce at critical demand zone.

PLAN YOUR TRADES AND TRADE YOUR PLANS

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. While the next few months will be a time of transition, a few things are likely. The Trump administration is expected to pursue a far looser regulatory policy than the outgoing Biden government. Plans for individual tax cuts are projected to drive consumer spending, while reductions in corporate taxes could deliver an immediate boost to earnings.

While recent market gains are largely driven by blue-chip giants, penny stocks quietly attract investors seeking untapped growth opportunities. Priced below $5 per share, the penny stocks offer a unique blend of risk and reward, with the potential to double or even triple initial investments.

The nature of these investments presents somewhat of a dilemma. How are investors supposed to separate the penny stocks that are ready to take off on an upward trajectory from those set to remain down in the dumps? This is where Wall Street’s analysts come into play.

We used the TipRanks database to uncover two compelling penny stocks that have earned Strong Buy ratings from the analyst community. According to the pros, these tickers are set to triple or more in the coming year. Let’s take a closer look.

Genelux Corporation (GNLX)

The first penny stock in the spotlight is Genelux, a clinical-stage biotech working in the world of immuno-oncology. Genelux’s research program is focused on the development of the next generation of cancer treatments, using oncolytic virotherapies to create therapeutic agents that can target a wide range of cancers. The company uses vaccinia virus to selectively replicate inside tumor cells and to kill them – while leaving the patient’s normal cells intact.

Genelux’s drug candidates target some of the more difficult-to-treat cancers, including a wide range of dangerous solid tumors, and are developed using the company’s CHOICE discovery platform. This is a proprietary platform that allows for the quick progression of new treatment candidates from early discovery through the clinical trial stages. Using its platform, Genelux has developed its leading oncolytic immunotherapy candidate, Olvi-Vec.

Olvi-Vec has been the subject of several early- and mid-phase clinical trials, but the current excitement around the drug candidate comes from the ongoing Phase 3 trial of the drug as an intraperitoneal (IPe) dosed treatment for platinum-resistant/refractory ovarian cancer (PRROC), a disease that is difficult to treat and has high unmet medical needs. The current Phase 3 trial will enroll up to 186 patients, and the company expects to release topline results in 2H25.

In addition to PRROC track, Genelux also has Olvi-Vec undergoing a Phase 2 trial in the treatment of non-small cell lung cancer (NSCLC). The interim readout for this trial is expected in the middle of next year.

Given these potential clinical milestones and GNLX’s current share price of $2.63, several members of the Street think that now is the right time to pull the trigger.

Roth MKM analyst Benjamin Paluch is particularly upbeat, suggesting that the Phase 3 ovarian cancer trial has the potential to be a game-changer for the stock.

“We view topline results from the Phase 3 study of Olvi-Vec in platinum resistant/refractory ovarian cancer as the key catalyst for the stock. Our base case is the trial is successful and shows a statistically significant progression-free survival (PFS)… Our base case assumes 70% upside with potential for a 100% gain under our bull case scenario and downside potentially limited to 30% under our bear case scenario… Recall, the FDA granted Fast Track designation to Olvi-Vec in platinum resistant/refractory ovarian cancer in November 2023, which suggests to us that the FDA could be flexible with its review, particularly in platinum refractory patients for which therapeutic options are limited,” Paluch opined.

To this end, Paluch rates GNLX a Buy along with a $10 price target. Should his thesis play out, a potential gain of 277% could be in the cards. (To watch Paluch’s track record, click here)

Other analysts don’t beg to differ. 4 Buy ratings and no Holds or Sells have been assigned in the last three months. Therefore, GNLX is a Strong Buy. The $15 average price target implies shares could climb 470% higher in the coming year. (See GNLX stock forecast)


SAB Biotherapeutics (SABS)

The next stock we’ll look at here is another biotherapeutic firm, SAB. This company has a focus on the treatment and prevention of immune and autoimmune diseases, a class of disease conditions that are known for the difficulties they present to both patients and care providers, in the form of dangerous symptoms and resistance to treatment.

SAB has developed an innovative genetic engineering platform, which it uses in the creation of new therapeutic agents. The company aims to develop multi-targeted, high-potency immunoglobulins (IgGs), and to do so without requiring human donors or even the use of convalescent plasma. While every biotech firm likes to say that it is unique, SAB is currently the only company on the scene capable of producing a truly polyclonal human antibody sans donor. These antibodies can be used to target diseases that present serious health challenges.

The company’s leading drug candidate, SAB-142, is a potential blockbuster if it pans out. SAB-142 offers a new approach to the treatment of type 1 diabetes (T1D), through disease modification. This drug candidate is a novel therapy for T1D, being a potentially redosable human antibody under study for its ability to delay the onset of clinical signs in, or the progression of, type 1 diabetes. SAB-142 is not insulin, nor would it require daily monitoring or management; in fact, the company sees a high chance that the drug could be administered on a one-yearly regimen.

In May of this year, SAB Biotherapeutics received clearance from the FDA to begin Phase 1 clinical testing of SAB-142 in the US. Enrollment for the Phase 1 trial has been completed, and the company expects to have a data readout by the end of this year. Early data showed no observation of serum sickness in the enrolled patients. SAB also has a Phase 1 trial underway in Australia, and expects to provide a data readout by year’s end.

These developments have drawn attention from Craig-Hallum analyst Albert Lowe, who has taken a closer look at the stock.

“We believe the company’s unique ability to produce human polyclonal antibodies (pAbs) offers profound opportunities for developing novel therapies, led by SAB-142. SAB-142 has a clear value proposition that builds on rabbit ATG’s (rATG) clinically validated mechanism of action in delaying the onset of T1D. As a human ATG, SAB-142 overcomes the safety limitations of rabbit ATG, making it a redosable disease-modifying therapy that enables long-term T1D disease prevention. We see opportunity for share appreciation as SAB-142 proceeds through development, where clinical data gives us confidence that SAB-142 can be the best-in-class therapy for long-term T1D prevention,” Lowe wrote.

In line with his optimistic take, Lowe rates SABS a Buy and set a price target of $11, which implies a potential upside of 237%. (To watch Lowe’s track record, click here)

Overall, all four of the recent analyst reviews on SABS are positive, making the Strong Buy consensus unanimous. The stock’s $3.26 trading price and $13.50 average target price combine to imply a 323% upside on the one-year horizon. (See SABS stock forecast)


To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Celestialsword:
The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. While the next few months will be a time of transition, a few things are likely. The Trump administration is expected to pursue a far looser regulatory policy than the outgoing Biden government. Plans for individual tax cuts are projected to drive consumer spending, while reductions in corporate taxes could deliver an immediate boost to earnings.

While recent market gains are largely driven by blue-chip giants, penny stocks quietly attract investors seeking untapped growth opportunities. Priced below $5 per share, the penny stocks offer a unique blend of risk and reward, with the potential to double or even triple initial investments.

The nature of these investments presents somewhat of a dilemma. How are investors supposed to separate the penny stocks that are ready to take off on an upward trajectory from those set to remain down in the dumps? This is where Wall Street’s analysts come into play.

We used the TipRanks database to uncover two compelling penny stocks that have earned Strong Buy ratings from the analyst community. According to the pros, these tickers are set to triple or more in the coming year. Let’s take a closer look.

Genelux Corporation (GNLX)

The first penny stock in the spotlight is Genelux, a clinical-stage biotech working in the world of immuno-oncology. Genelux’s research program is focused on the development of the next generation of cancer treatments, using oncolytic virotherapies to create therapeutic agents that can target a wide range of cancers. The company uses vaccinia virus to selectively replicate inside tumor cells and to kill them – while leaving the patient’s normal cells intact.

Genelux’s drug candidates target some of the more difficult-to-treat cancers, including a wide range of dangerous solid tumors, and are developed using the company’s CHOICE discovery platform. This is a proprietary platform that allows for the quick progression of new treatment candidates from early discovery through the clinical trial stages. Using its platform, Genelux has developed its leading oncolytic immunotherapy candidate, Olvi-Vec.

Olvi-Vec has been the subject of several early- and mid-phase clinical trials, but the current excitement around the drug candidate comes from the ongoing Phase 3 trial of the drug as an intraperitoneal (IPe) dosed treatment for platinum-resistant/refractory ovarian cancer (PRROC), a disease that is difficult to treat and has high unmet medical needs. The current Phase 3 trial will enroll up to 186 patients, and the company expects to release topline results in 2H25.

In addition to PRROC track, Genelux also has Olvi-Vec undergoing a Phase 2 trial in the treatment of non-small cell lung cancer (NSCLC). The interim readout for this trial is expected in the middle of next year.

Given these potential clinical milestones and GNLX’s current share price of $2.63, several members of the Street think that now is the right time to pull the trigger.

Roth MKM analyst Benjamin Paluch is particularly upbeat, suggesting that the Phase 3 ovarian cancer trial has the potential to be a game-changer for the stock.

“We view topline results from the Phase 3 study of Olvi-Vec in platinum resistant/refractory ovarian cancer as the key catalyst for the stock. Our base case is the trial is successful and shows a statistically significant progression-free survival (PFS)… Our base case assumes 70% upside with potential for a 100% gain under our bull case scenario and downside potentially limited to 30% under our bear case scenario… Recall, the FDA granted Fast Track designation to Olvi-Vec in platinum resistant/refractory ovarian cancer in November 2023, which suggests to us that the FDA could be flexible with its review, particularly in platinum refractory patients for which therapeutic options are limited,” Paluch opined.

To this end, Paluch rates GNLX a Buy along with a $10 price target. Should his thesis play out, a potential gain of 277% could be in the cards. (To watch Paluch’s track record, click here)

Other analysts don’t beg to differ. 4 Buy ratings and no Holds or Sells have been assigned in the last three months. Therefore, GNLX is a Strong Buy. The $15 average price target implies shares could climb 470% higher in the coming year. (See GNLX stock forecast)


SAB Biotherapeutics (SABS)

The next stock we’ll look at here is another biotherapeutic firm, SAB. This company has a focus on the treatment and prevention of immune and autoimmune diseases, a class of disease conditions that are known for the difficulties they present to both patients and care providers, in the form of dangerous symptoms and resistance to treatment.

SAB has developed an innovative genetic engineering platform, which it uses in the creation of new therapeutic agents. The company aims to develop multi-targeted, high-potency immunoglobulins (IgGs), and to do so without requiring human donors or even the use of convalescent plasma. While every biotech firm likes to say that it is unique, SAB is currently the only company on the scene capable of producing a truly polyclonal human antibody sans donor. These antibodies can be used to target diseases that present serious health challenges.

The company’s leading drug candidate, SAB-142, is a potential blockbuster if it pans out. SAB-142 offers a new approach to the treatment of type 1 diabetes (T1D), through disease modification. This drug candidate is a novel therapy for T1D, being a potentially redosable human antibody under study for its ability to delay the onset of clinical signs in, or the progression of, type 1 diabetes. SAB-142 is not insulin, nor would it require daily monitoring or management; in fact, the company sees a high chance that the drug could be administered on a one-yearly regimen.

In May of this year, SAB Biotherapeutics received clearance from the FDA to begin Phase 1 clinical testing of SAB-142 in the US. Enrollment for the Phase 1 trial has been completed, and the company expects to have a data readout by the end of this year. Early data showed no observation of serum sickness in the enrolled patients. SAB also has a Phase 1 trial underway in Australia, and expects to provide a data readout by year’s end.

These developments have drawn attention from Craig-Hallum analyst Albert Lowe, who has taken a closer look at the stock.

“We believe the company’s unique ability to produce human polyclonal antibodies (pAbs) offers profound opportunities for developing novel therapies, led by SAB-142. SAB-142 has a clear value proposition that builds on rabbit ATG’s (rATG) clinically validated mechanism of action in delaying the onset of T1D. As a human ATG, SAB-142 overcomes the safety limitations of rabbit ATG, making it a redosable disease-modifying therapy that enables long-term T1D disease prevention. We see opportunity for share appreciation as SAB-142 proceeds through development, where clinical data gives us confidence that SAB-142 can be the best-in-class therapy for long-term T1D prevention,” Lowe wrote.

In line with his optimistic take, Lowe rates SABS a Buy and set a price target of $11, which implies a potential upside of 237%. (To watch Lowe’s track record, click here)

Overall, all four of the recent analyst reviews on SABS are positive, making the Strong Buy consensus unanimous. The stock’s $3.26 trading price and $13.50 average target price combine to imply a 323% upside on the one-year horizon. (See SABS stock forecast)


To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

I think biotechs PH3 trials would be fantastic in the long run ENSC some hedgeies have been positioning since about 2 weeks ago with, 3 firm have taken up about 28% of the biotech company now. If their PH3 is successful the stock can do 1500% though nasdaq gave them 19th of December to hit 1$+ if the stock can get over 1$ and beat nasdaq wahala with success of PH3 trial+ FDA approval then it can do 10-25$ with time. Am still holding at 94% it was even 124% before the pull back I will hold till next year by God grace for the outcome of their clinical trials of PH3 then subsequent FDA approvals.

Health stocks will always carry 90% of my portfolio

aremso:


I think biotechs PH3 trials would be fantastic in the long run ENSC some hedgeies have been positioning since about 2 weeks ago with, 3 firm have taken up about 28% of the biotech company now. If their PH3 is successful the stock can do 1500% though nasdaq gave them 19th of December to hit 1$+ if the stock can get over 1$ and beat nasdaq wahala with success of PH3 trial+ FDA approval then it can do 10-25$ with time. Am still holding at 94% it was even 124% before the pull back I will hold till next year by God grace for the outcome of their clinical trials of PH3 then subsequent FDA approvals.

Health stocks will always carry 90% of my portfolio

You are one hundred percent correct

3 Growth Stocks Down 84%, 28%, and 97% to Buy Right Now

Investors flinched at Roku's Q4 guidance and subsequently lost sight of the bigger bullish picture.
Hydrogen fuel cells may finally be entering the mainstream. Plug Power stands ready.
Arm Holdings' computer processor architecture is proving increasingly popular for one simple but insurmountable reason.
Motley Fool Issues Rare “All In” Buy Alert
The sellers have not only overshot their targets but have done so at the worst possible time.

While the broad market may be uncomfortably near record highs right now, this isn't the case for every stock. Some tickers not only didn't get swept higher by the recent marketwide rally, but they are trading down from their peak prices. Fortunately, it's likely for reasons that won't last.

Here are three discounted growth stocks you might want to consider buying while they're still trading at sale prices. Their long-term bullish cases are still well intact.

1. Roku
If you've been keeping tabs on Roku (ROKU -7.33%) of late then you likely know a budding rebound was upended at the end of last month. Although its third-quarter sales and its earnings before interest, taxes, depreciation, and amortization (EBITDA) were both up year over year and its top and bottom lines each topped expectations, guidance for the quarter now underway was disappointing. The company forecasted revenue of $465 million versus the analysts' consensus forecast of $477 million, while Roku's projected Q3 EBITDA of $30 million is short of analysts' expectation of $36.2 million. The immediate post-earnings sell-off now leaves Roku shares 28% below their late-2023 high, and down 84% from their 2021 peak price.


NASDAQ: ROKU
Roku
Today's Change
(-7.33%) -US$5.45
Current Price
US$68.87
However, the market is missing a couple of key things about this company's business.

First, Roku is in the habit of topping estimates regardless of its guidance. In fact, not counting the unpredictable years of 2022 and 2023 -- when the company was also logging regular losses by investing heavily in its future growth -- Roku has reliably beat analysts' consensus earnings estimates.

And the second (and much bigger) point many investors are underappreciating? The reach of Roku's streaming ecosystem.

As of Pixalate's most recent look, Roku accounts for 37% of North America's connected television market. The next nearest noteworthy rival is Amazon's FireTV platform, but at only 15% market share it enjoys less than half of Roku's domestic reach. Roku's also doing very well in overseas markets like Latin America, where it's made a concerted effort to establish itself.

Being the brand name behind the continent's most popular streaming platform is only half the bullish argument though. Roku is also part of the streaming content landscape. Numbers from TV-ratings service Nielsen say The Roku Channel is more watched within the U.S. than Warner Bros. Discovery's HBO Max or Paramount's Paramount+. That's not insignificant for Roku's home-grown ad-supported streaming service.

Of course, Roku is just riding the ongoing growth of the streaming business, which Precedence Research reports is set to grow at an average annual pace of 21% through 2034.

2. Plug Power
After years of losses and poor performance from its stock, in 2020 it finally looked as if Plug Power (PLUG -5.08%) was turning the corner. Shares rallied from less than $2 then to an early 2021 high of $75.49, with pandemic-prompted lockdowns providing investors plenty of time to fall in love with the idea of turning hydrogen fuel into electricity.

The bullishness wouldn't last though. Shares have since given up all of that gain, with investors recognizing that profits remain elusive.

The market has become even more pessimistic about Plug Power's prospects since Donald Trump's election, as the president-elect appears to be more in favor of proven fossil fuels and has openly derided hydrogen fuel as being dangerous. The company's recently ended Q3 results didn't help either. Not only was revenue of $173.7 million down 12% year over year, but it also fell short of the $207.8 million analysts were expecting.


NASDAQ: PLUG
Plug Power
Today's Change
(-5.08%) -US$0.10
Current Price
US$1.87
As difficult as it may be to step into a stake in this seemingly struggling company right now, however, the 97% pullback from its 2021 peak may be a prime opportunity to dive in.

See, hydrogen fuel cells like the ones Plug Power manufactures are a key component of energy's future. This type of electricity production leaves no carbon footprint. Although it takes energy to split water into oxygen and hydrogen used by fuel cells to generate electricity, the necessary electrolysis process can be achieved using similarly clean energy sources like solar, or even nuclear power. Hydrogen fuel cells can then be used to electrically power practical equipment like forklifts, automobiles, and even buildings.

So far consumer and institutional interest in this environmentally friendly alternative has been modest. We could be at a turning point though. An outlook from Straits Research suggests the global fuel cell market is poised to grow at an annualized pace of nearly 26% through 2032, with most of this growth taking shape during the latter half of this time frame.

3. Arm Holdings
Finally, when most investors think of computer processors, names like Intel, Qualcomm, and Nvidia come to mind. And understandably so. Their chips are not only found in most personal computers, but they also serve as the brains of many data centers.

As time marches on though, the limitations of Intel's and Qualcomm's architectures are turning into outright hurdles. Developers are finding alternative processing platforms like those offered by Arm Holdings (ARM -5.59%) are better suited for certain applications. Chief among Arm's advantages is greater power efficiency, which in turn makes them well suited for use in mobile devices doing heavy-duty artificial intelligence (AI) work. That's a big reason Apple chose Arm processors for its new AI-capable iPhones.


NASDAQ: ARM
Arm Holdings
Today's Change
(-5.59%) -US$7.62
Current Price
US$128.73
Interest in Arm's technology doesn't end there, however. As the development of Arm-based processors progresses the world is increasingly using them in data centers instead of silicon made by the aforementioned Intel and Advanced Micro Devices. Even Apple itself is reportedly venturing into these waters by designing its own data center silicon around Arm's architecture.

And well it should. Apple's license to use Arm's intellectual property is good until at least 2040.

In this vein, it's important to understand that Arm is predominantly a licensor of intellectual property, as opposed to being a foundry or manufacturer. This means it only generates a modest amount of revenue relative to the rest of the chipmaking industry.

It's consistent and consistently high-margin revenue though, fueled by the fact that about half of all the world's processors -- often the ones you don't think about -- are Arm-based, while nearly 100% of all smartphones use some sort of Arm processor. The stock's 28% pullback from July's high is apt to be a short-lived buying opportunity.


© 1995 - 2024 The Motley Fool. All rights reserved.

TARGET TECHNICAL ANALYSIS EARLY MARKET COMMENTS 18 NOVEMBER 2024
Market can spring up surprises. Today we are likely to start the week bullish despite the extreme overbought conditions of some stocks.
Our caucus members will receive message on how we can participate in gains on strong stocks for the long term. We are talking about the AI, Blockchain themes even China. This is a strategy for the risk averse investor to eat their cake and still have it. I hope we can still remember the pending (sorry, it should land in our wallet today) NGN2 on NGN16 stock and this will be monthly, other months can be NGN1, we do not need to worry it is like collecting monthly rent.

Wish all a fruitful week. Again shout out to our "GO", I will assure my GO that people like us will not abandon the forum, both in good and trying periods. Increase in engagements here is good. At least our NSEMPA friends will be happy with us, that we are keeping on despite the initial challenges we expect more of them to add this to their go to forum to make money on investing on a global level.

Analyst can sometimes spoil person show ooo I entered EYEN after massive drop of 70% last week due to failure of their PH3 trial then after waiting endlessly to get it more at a crushed price then I manage bought at 0.113 then boom to 0.125 only for analyst do down grade from buy to hold wit TP from 12-2.😂😂😂😂

They are playing I will still exit at 0.25😂😂😂

aremso:
Analyst can sometimes spoil person show ooo I entered EYEN after massive drop of 70% last week due to failure of their PH3 trial then after waiting endlessly to get it more at a crushed price then I manage bought at 0.113 then boom to 0.125 only for analyst do down grade from buy to hold wit TP from 12-2.😂😂😂😂

They are playing I will still exit at 0.25😂😂😂

@aremso, curiosity made me check EYEN chart. Just wondering why you bought into the stock? Is it because of the massive fall?
EYEN outlook still bearish. YES! you can exit at 0.25 - smart plan; but risky!

BullBearMkt:

@aremso, curiosity made me check EYEN chart. Just wondering why you bought into the stock? Is it because of the massive fall?
EYEN outlook still bearish. YES! you can exit at 0.25 - smart plan; but risky!

Bro. TCRT had same pattern last year with over 200m float my average then was 0.09 then Mr. TCRT began to dig ground looking for what was not lost till it got to 0.04 . Boom from 0.04 the stock did 0.27 from 0.04 somebody here said she was tired of holding she sold like today the stock hit over 100% next day. You see all these health stocks has their uniqueness, even has this failed PH3 trial they can announce merger tomorrow now and u see it running 300%. A lot of madness in that health sector but I love the madness, that madness create money. ENSC did 157% wtout any info then madly Shorted the next day loosing around 90% was watching and at 0.34 I entered thinking that was the support and bounce back to 0.36 and I was on gain only to resume dump and voom I was loosing over 200$ until it gets to 0.30 where it established solid support. The rest is history am fluctuating between 94-103% gain and am holding till their PH3 trial and FDA next year by God grace. If both works fine the gap up Will be massive

aremso:


Bro. TCRT had same pattern last year with over 200m float my average then was 0.09 then Mr. TCRT began to dig ground looking for what was not lost till it got to 0.04 . Boom from 0.04 the stock did 0.27 from 0.04 somebody here said she was tired of holding she sold like today the stock hit over 100% next day. You see all these health stocks has their uniqueness, even has this failed PH3 trial they can announce merger tomorrow now and u see it running 300%. A lot of madness in that health sector but I love the madness, that madness create money. ENSC did 157% wtout any info then madly Shorted the next day loosing around 90% was watching and at 0.34 I entered thinking that was the support and bounce back to 0.36 and I was on gain only to resume dump and voom I was loosing over 200$ until it gets to 0.30 where it established solid support. The rest is history am fluctuating between 94-103% gain and am holding till their PH3 trial and FDA next year by God grace. If both works fine the gap up Will be massive

It seems you've mastered the art very well. Best of luck bro!

BullBearMkt:

It seems you've mastered the art very well. Best of luck bro!

Bro u are still the Don oo just trying to study health stocks and see how I can make money out of them as they have catalyst apart from their financial statements unlike othe stocks that has Fundamentals majorly as their catalyst and sometimes they have same patterns. TCRT lost 65% in a day last year around august based on their failed PH3 trial EYEN lost 70% on Friday based on their failed PH3 trial too. So just trying to see how I can make few dollars from these stocks and above all na still God ooo as I don't know anything

TARGET TECHNICAL ANALYSIS EARLY MARKET COMMENTS 18 NOVEMBER 2024

Internationally the market is just giving indication that AI is the buzz word and it seems to have taken over every facet of our life (or where it is not been mentioned, something is there that people will now start calling AI in the future, e.g in biotechs, there are the robots that are used in performing operations, theses have always been there, check out 'intuitive surgical stock" but it is not yet being emphasised). So, uptrend will continue due to AI and fortunately too with the the Elon/Trump influence everything AI will likely boom and then drag the market along, we should know, also AI needs power (currently nuclear is the partner here plus anything that will reduce power cost ,SMCI is still a key factor here despite problem with Financial records).

So we need to allign ourself with the language of the market. Our trading ideas is alreadi in the hand of our causcus members. Today we are referencing a chartin plaform which any serious player in the market will know. For me I can ignore all websites, if I just have this platform plus 3 others, I am okay and I will come upwith top stop picks. So if you want to start knowing stocks to buy on your own without waiting for anybody, you will also know when to sell. The are the benefits our caucus members are enjoying!!! We do not have dull moments

ADVANCE NOTICE FOR TOMMORROW 20 NOVEMBER 2024
Expect a fairly bullish day tomorrow, the techs are going to fire on full cylinders. Our Caucus has been notified how to prepare for this. Only caution is that we should not negotiate on quality. Like I saw one long story here, for us who are old timers and we sleep, dream and eat this market a stock like FCEL is a no go area, don't buy such stock if you value your money

yok:
TARGET TECHNICAL ANALYSIS EARLY MARKET COMMENTS 18 NOVEMBER 2024

Internationally the market is just giving indication that AI is the buzz word and it seems to have taken over every facet of our life (or where it is not been mentioned, something is there that people will now start calling AI in the future, e.g in biotechs, there are the robots that are used in performing operations, theses have always been there, check out 'intuitive surgical stock" but it is not yet being emphasised). So, uptrend will continue due to AI and fortunately too with the the Elon/Trump influence everything AI will likely boom and then drag the market along, we should know, also AI needs power (currently nuclear is the partner here plus anything that will reduce power cost ,SMCI is still a key factor here despite problem with Financial records).

So we need to allign ourself with the language of the market. Our trading ideas is alreadi in the hand of our causcus members. Today we are referencing a chartin plaform which any serious player in the market will know. For me I can ignore all websites, if I just have this platform plus 3 others, I am okay and I will come upwith top stop picks. So if you want to start knowing stocks to buy on your own without waiting for anybody, you will also know when to sell. The are the benefits our caucus members are enjoying!!! We do not have dull moments

Thanks for the heads up always, I will make other 10% of my holding in AI stocks. Let me begin to look for those growth badly damaged one among them that fits my strategies